Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Next Previous
Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobolimab (Primary) ; Docetaxel; Dostarlimab; Encelimab; Nivolumab
  • Indications Colorectal cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Peritoneal cancer; Skin cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms AMBER
  • Sponsors GlaxoSmithKline; GSK; TESARO

    • Most Recent Events

    • 09 Dec 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 369 to 475, treatment arm changed from 15 to 16
    • 09 Dec 2022 Planned number of patients changed from 369 to 475.
    • 09 Dec 2022 Planned End Date changed from 3 Oct 2024 to 15 Jul 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top